相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
Prajakta S. Badri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir
Erik Mogalian et al.
CLINICAL PHARMACOKINETICS (2016)
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
Stefan Zeuzem et al.
JOURNAL OF HEPATOLOGY (2016)
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection A Randomized Trial
Stephen Pianko et al.
ANNALS OF INTERNAL MEDICINE (2015)
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir
Brian J. Kirby et al.
CLINICAL PHARMACOKINETICS (2015)
Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned
David J. Back et al.
GASTROENTEROLOGY (2015)
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
Raymond T. Chung et al.
HEPATOLOGY (2015)
Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection
Anu Osinusi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1 A Randomized Trial
Mark S. Sulkowski et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
EFFICACY AND SAFETY OF GRAZOPREVIR AND ELBASVIR IN HEPATITIS C GENOTYPE 1-INFECTED PATIENTS WITH CHILD-PUGH CLASS B CIRRHOSIS (C-SALT PART A)
I. M. Jacobson et al.
JOURNAL OF HEPATOLOGY (2015)
Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir
Rajeev M. Menon et al.
JOURNAL OF HEPATOLOGY (2015)
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
Mark Sulkowski et al.
LANCET (2015)
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
Jean-Michel Molina et al.
LANCET (2015)
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
David Roth et al.
LANCET (2015)
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
M. P. Curry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
G. R. Foster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
J. J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
D. L. Wyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
Juergen K. Rockstroh et al.
LANCET HIV (2015)
Ribavirin Improves the IFN-γ Response of Natural Killer Cells to IFN-Based Therapy of Hepatitis C Virus Infection
Jens M. Werner et al.
HEPATOLOGY (2014)
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Mark S. Sulkowski et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT
E. Mogalian et al.
JOURNAL OF HEPATOLOGY (2014)
HCV and HIV co-infection: mechanisms and management
Jennifer Y. Chen et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2014)
Pharmacokinetics, Safety, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor for Hepatitis C Virus, following Single Ascending Doses in Healthy Subjects
Jill Denning et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir
Marc Bifano et al.
ANTIVIRAL THERAPY (2013)
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
JOURNAL OF HEPATOLOGY (2013)
Effect of Dietary Purines on the Pharmacokinetics of Orally Administered Ribavirin
Linghui Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy
JK Rockstroh et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients
M Pérez-Olmeda et al.
AIDS (2003)
Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus
C Martinez-Sierra et al.
CLINICAL INFECTIOUS DISEASES (2003)
Mitochondrial toxic effects and ribavirin
D Salmon-Céron et al.
LANCET (2001)
分享论文
